Since the passage of the False Claims Act in 1986, the federal government has recovered about $22 billion through qui tam, or whistleblower lawsuits and a fair number of these have emanated from the pharmaceutical industry. An untold number of such lawsuits are always in the wings, as people who work with or for drugmakers attempt to expose alleged wrongdoing.
There have been accusations that some whistleblowers are only in it for the money (see this), but life as a whistleblower has its challenges (see here). And so concerned that the pharmaceutical industry may not be doing enough to educate employees about whistleblowing protection, US Senator Chuck Grassley has written 16 big drugmakers to provide information about their programs.
The letters went to Abbott Labs, Amgen, AstraZeneca, Bristol-Myers Squibb, Eisai, Eli Lilly, Forest Laboratories, GlaxoSmithKline, Hoffmann-La Roche, Johnson & Johnson, Merck, Novartis, Pfizer, Sanofi-Aventis, Takeda Pharmaceuticals and Boehringer Ingelheim.
pic thx to katerha on flickr